Skip to content
Baker Capital StrategiesMARKETS. FILINGS. PERSPECTIVE.
Powered by THEMA

BAKER CAPITAL STRATEGIES

Get the free weekly BCS email.

Selected company filings and market updates, delivered by email. Your first report will follow soon.

  • Your weekly BCS reportMarket updates and links to filings you can explore.
  • THEMA at launchWe’ll send directions for setting up your filing alerts when THEMA officially opens.

One signup for the weekly email and your free THEMA Basic account at launch.

Already registered or a CSW member?Log in to THEMA →

At least 8 characters. This also creates your free THEMA account for launch.

You’re signing up for the weekly BCS email and THEMA launch/setup updates. Unsubscribe using the link in any email. Privacy policy · Terms

BCS
Home/The Filing Wire/PharmaCyte Biotech, Inc./ 10-K

Annual Report · 10-K

PharmaCyte Biotech, Inc.

PMCBNASDAQEQUITYCurrent

Annual Report

Filed Jul 29, 2026Accepted Jul 29, 2026, 12:58 PM EDTCIK 1157075Accession 0001683168-26-005836
View company →Permanent SEC source ↗
Share

Company context

Current securities

PMCBNASDAQ · EQUITY · Current
Historical securities (4)
NVLXOTC · EQUITY · Historical · closed Jan 8, 2015PMCBOTC · EQUITY · Historical · closed Jul 12, 2021PMCBOTC · EQUITY · Historical · closed Aug 10, 2021PMCBDOTC · EQUITY · Historical · closed Aug 9, 2021

Recent company filings

  1. Changes in Registrant's Certifying AccountantOct 16, 2026
  2. 10-Q filingSep 14, 2026
  3. 4/A filingJul 17, 2026
  4. 4/A filingJul 17, 2026
  5. 4/A filingJul 17, 2026

Registered securities in this filing

PHARMACYTE BIOTECH, INC. · 10-K · Filed 2026-07-29

As filed in this accession. Current/historical status below comes from the governed listing record; the cover itself remains exact to this filing.

Common Stock, Par Value $0.0001 Per Share

Symbol
PMCB
Exchange
NASDAQ
Classification
COMMON
Filing context

Context: From2025-05-01to2026-04-30

Dimensions: Not supplied

Accession 000168316826005836 · 1 registered-security cover member

Read the exact SEC filing ↗

As-filed source

Primary evidence
As filedOpen full document ↗

Privacy choices

BCS measures page use with Google Analytics using regional consent settings. You can change your preference here. Charts and market data remain available.

Essential functions — always available. Security, navigation, registration and remembering these choices.

Audience analytics

Analytics cookies are off by default for visitors Google identifies in the EEA, UK or Switzerland until allowed. Limited measurement without analytics cookies may still occur under those regional defaults.

TradingView charts, quotes and the economic calendar load automatically as page content. TradingView receives network and browser information and may collect its own usage analytics. This choice controls BCS’s Google Analytics only.

Google advertising is not enabled. Direct sponsor links do not load advertising trackers on BCS.

Turning analytics off stops future Google Analytics activity here. It does not erase information already received by the provider. Read the privacy policy.